2018 / 06

Next Paper
DOI: 10.24075/brsmu.2018.086

OPINION

Magnetic resonance imaging for predicting personalized antitumor nanomedicine efficacy

Naumenko VA1, Garanina AS2, Vodopyanov SS1, Nikitin AA1,2, Prelovskaya AO1, Demihov EI4, Abakumov MA1,3, Majouga AM1,2,5, Chekhonin VP3
About authors

1 Laboratory of Biomedical Nanomaterials National University of Science and Technology MISiS, Moscow

2 Research Laboratory of Tissue-Specific Ligands, Faculty of Chemistry Federal State Budget Educational Institution of Higher Education MV Lomonosov Moscow State University, Moscow

3 Pirogov Russian National Research Medical University, Moscow, Russia

4 Lebedev Physical Institute, Russian Academy of Sciences, Moscow

5 Mendeleyev University of Chemical Technology of Russia, Moscow

Correspondence should be adressed: Viktor A. Naumenko
Leninsky 4, Moscow, 119049; moc.liamg@tciv.oknemuan

About paper

Funding: the study was financially supported by the Ministry of Education and Science of the Russian Federation under the Federal Targeted Programme for Research and Development in Priority Areas of Development of the Russian Scientific and Technological Complex for 2014–2020, Agreement #14.575.21.0147 of 27.09.2017 (Agreement ID RFMEFI57517X0147).

Received: 2018-08-30 Accepted: 2018-09-25 Published online: 2018-12-31
|
  1. Shi J et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. NIH Public Access, 2017; 17 (1): 20–37.
  2. Prabhakar U et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013; 73 (8): 2412–17.
  3. Davis ME et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464 (7291): 1067–70.
  4. Hrkach J et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012; 4 (128): 128ra39.
  5. Miller MA et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med. 2015; 7 (314): 314ra183.
  6. Ramanathan RK et al. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clin Cancer Res. 2017; 23 (14): 3638–48.
  7. Wilhelm S et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016; 1 (5): 16014.
  8. Karathanasis E et al. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology. 2009; 250 (2): 398–406.
  9. Lee H et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017; 23 (15): 4190–02.
  10. Head HW et al. Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology. 2010; 255 (2): 405–14.
  11. Arrieta O et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014; 73 (5): 975–82.
  12. Yokoi K et al. Capillary-Wall Collagen as a Biophysical Marker of Nanotherapeutic Permeability into the Tumor Microenvironment. Cancer Res. 2014; 74 (16): 4239–46.
  13. Yokoi K et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett. 2014; 345 (1): 48–55.
  14. Sessa C et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol. 2008; 5 (7): 378–91.
  15. Sherwood LM, Parris EE, Folkman J. Tumor Angiogenesis: Therapeutic Implications. N Engl J Med. 1971; 285 (21): 1182–6.